Cargando…

CAN IgG ANTIBODIES DIRECTED AGAINST DIFFERENT TARGETS SOLVE THE PROBLEM OF FALSE-POSITIVE RESULTS IN SARS-CoV-2 SEROLOGY?

In addition to RT-PCR assays, serology testing that has been recognized as a useful tool to assess the spread of infection in the population is considered successful and important strategy in the control of the global pandemic of SARS-CoV-2 infection. Now, a great number of manufacturers offer their...

Descripción completa

Detalles Bibliográficos
Autores principales: Beader, Nataša, Mareković, Ivana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196218/
https://www.ncbi.nlm.nih.gov/pubmed/35734484
http://dx.doi.org/10.20471/acc.2021.60.04.25
_version_ 1784727135434309632
author Beader, Nataša
Mareković, Ivana
author_facet Beader, Nataša
Mareković, Ivana
author_sort Beader, Nataša
collection PubMed
description In addition to RT-PCR assays, serology testing that has been recognized as a useful tool to assess the spread of infection in the population is considered successful and important strategy in the control of the global pandemic of SARS-CoV-2 infection. Now, a great number of manufacturers offer their serologic tests on the market. When interpretating the results, the rate of seroprevalence should be taken in consideration because it may influence the positive predictive value, as well as cross-reactivity with other coronaviruses in case of assays with poorly designed antigens. We present results of 11 patients with different clinical background and tested with two different serologic tests, DIAPRO (ELISA; Sesto San Giovanni, Italy) and VIDAS (ELFA; BioMerieux, Marcy I’Etoile, France). The results obtained by the former test showed ten of these patients to be IgG positive and one patient was IgG weakly positive with different confidence index. The latter test discriminated positive results with medium confidence index on the former test as negative. The results obtained with two serology tests were concordant with the observation that the results with medium confidence index may indicate cross-reactivity.
format Online
Article
Text
id pubmed-9196218
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb
record_format MEDLINE/PubMed
spelling pubmed-91962182022-06-21 CAN IgG ANTIBODIES DIRECTED AGAINST DIFFERENT TARGETS SOLVE THE PROBLEM OF FALSE-POSITIVE RESULTS IN SARS-CoV-2 SEROLOGY? Beader, Nataša Mareković, Ivana Acta Clin Croat Preliminary Communications In addition to RT-PCR assays, serology testing that has been recognized as a useful tool to assess the spread of infection in the population is considered successful and important strategy in the control of the global pandemic of SARS-CoV-2 infection. Now, a great number of manufacturers offer their serologic tests on the market. When interpretating the results, the rate of seroprevalence should be taken in consideration because it may influence the positive predictive value, as well as cross-reactivity with other coronaviruses in case of assays with poorly designed antigens. We present results of 11 patients with different clinical background and tested with two different serologic tests, DIAPRO (ELISA; Sesto San Giovanni, Italy) and VIDAS (ELFA; BioMerieux, Marcy I’Etoile, France). The results obtained by the former test showed ten of these patients to be IgG positive and one patient was IgG weakly positive with different confidence index. The latter test discriminated positive results with medium confidence index on the former test as negative. The results obtained with two serology tests were concordant with the observation that the results with medium confidence index may indicate cross-reactivity. Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2021-12 /pmc/articles/PMC9196218/ /pubmed/35734484 http://dx.doi.org/10.20471/acc.2021.60.04.25 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Preliminary Communications
Beader, Nataša
Mareković, Ivana
CAN IgG ANTIBODIES DIRECTED AGAINST DIFFERENT TARGETS SOLVE THE PROBLEM OF FALSE-POSITIVE RESULTS IN SARS-CoV-2 SEROLOGY?
title CAN IgG ANTIBODIES DIRECTED AGAINST DIFFERENT TARGETS SOLVE THE PROBLEM OF FALSE-POSITIVE RESULTS IN SARS-CoV-2 SEROLOGY?
title_full CAN IgG ANTIBODIES DIRECTED AGAINST DIFFERENT TARGETS SOLVE THE PROBLEM OF FALSE-POSITIVE RESULTS IN SARS-CoV-2 SEROLOGY?
title_fullStr CAN IgG ANTIBODIES DIRECTED AGAINST DIFFERENT TARGETS SOLVE THE PROBLEM OF FALSE-POSITIVE RESULTS IN SARS-CoV-2 SEROLOGY?
title_full_unstemmed CAN IgG ANTIBODIES DIRECTED AGAINST DIFFERENT TARGETS SOLVE THE PROBLEM OF FALSE-POSITIVE RESULTS IN SARS-CoV-2 SEROLOGY?
title_short CAN IgG ANTIBODIES DIRECTED AGAINST DIFFERENT TARGETS SOLVE THE PROBLEM OF FALSE-POSITIVE RESULTS IN SARS-CoV-2 SEROLOGY?
title_sort can igg antibodies directed against different targets solve the problem of false-positive results in sars-cov-2 serology?
topic Preliminary Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196218/
https://www.ncbi.nlm.nih.gov/pubmed/35734484
http://dx.doi.org/10.20471/acc.2021.60.04.25
work_keys_str_mv AT beadernatasa caniggantibodiesdirectedagainstdifferenttargetssolvetheproblemoffalsepositiveresultsinsarscov2serology
AT marekovicivana caniggantibodiesdirectedagainstdifferenttargetssolvetheproblemoffalsepositiveresultsinsarscov2serology